NVCR:NGS-NovoCure Limited (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 23.15

Change

0.00 (0.00)%

Market Cap

USD 0.81B

Volume

0.82M

Analyst Target

USD 79.57
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NovoCure Ltd is a commercial stage oncology company. It is engaged in the development, manufacture and commercialization of tumor treating fields for the treatment of solid tumors.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-26 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 46.05B
ALGN Align Technology Inc

N/A

USD 19.27B
PODD Insulet Corporation

N/A

USD 13.41B
SWAV Shockwave Medical Inc

N/A

USD 12.57B
BRKR Bruker Corporation

N/A

USD 9.79B
MASI Masimo Corporation

N/A

USD 6.66B
TMDX TransMedics Group Inc

N/A

USD 4.52B
PRCT Procept Biorobotics Corp

N/A

USD 3.54B
AXNX Axonics Modulation Technologie..

N/A

USD 3.43B
TNDM Tandem Diabetes Care Inc

N/A

USD 3.20B

ETFs Containing NVCR

XHE SPDR® S&P Health Care Eq.. 2.26 % 0.35 %

N/A

USD 0.26B
DOCG:LSE L&G Healthcare Breakthrou.. 2.11 % 0.00 %

N/A

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 2.11 % 0.00 %

N/A

USD 0.07B
XMLH:XETRA L&G Healthcare Breakthrou.. 2.09 % 0.00 %

N/A

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 2.09 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 2.09 % 0.00 %

N/A

USD 0.07B
DWAQ 0.00 % 0.60 %

N/A

N/A
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.06B
NIFE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 55.06% 87% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.06% 87% B+ 91% A-
Trailing 12 Months  
Capital Gain -68.53% 30% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.53% 30% F 12% F
Trailing 5 Years  
Capital Gain -56.77% 53% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.77% 53% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -0.71% 49% F 43% F
Dividend Return -0.71% 49% F 38% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 81.04% 37% F 19% F
Risk Adjusted Return -0.88% 50% F 40% F
Market Capitalization 0.81B 85% B 78% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1,480.87 2% 0%
Price/Book Ratio 4.01 44% 27%
Price / Cash Flow Ratio -24.17 88% 89%
Price/Free Cash Flow Ratio -6.42 77% 79%
Management Effectiveness  
Return on Equity -48.70% 56% 32%
Return on Invested Capital -25.61% 61% 31%
Return on Assets -11.18% 64% 32%
Debt to Equity Ratio 156.92% 16% 14%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector